Navigation Links
Kewaunee Scientific Reports Results for Second Quarter

STATESVILLE, N.C., Dec. 3, 2013 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its second quarter ended October 31, 2013.

Net earnings for the quarter were $725,000, or $0.28 per diluted share, as compared to net earnings of $649,000, or $0.25 per diluted share, in the second quarter last year. A favorable product mix, lower operating costs, and the favorable impact of the Company's previously reported buyout of the minority interest in its principal international subsidiary more than offset the unfavorable impact of lower sales during the quarter.

Sales for the quarter were $26,098,000, as compared to sales of $31,185,000 in the second quarter last year. Domestic Operations sales were $22,061,000, as compared to sales of $25,683,000 in the second quarter last year. A substantial portion of the decline in domestic sales was anticipated as part of the previously reported strategy underway by the Company to sell more laboratory projects through its dealer network, with the Company providing the manufactured products and the dealers providing related project management, installation and other service activities. International Operations sales for the quarter were $4,037,000, down from $5,502,000 in the second quarter last year. International Operations sales in the second quarter of the prior year were increased by the shipments of several large projects during that quarter.

The order backlog was $69.5 million at October 31, 2013, as compared to $71.1 million at July 31, 2013. Fewer laboratory construction projects of all sizes, public and private, were available in the domestic laboratory market during the quarter, as customers appeared hesitant to move forward on projects because of ongoing political and economic uncertainty. A decline in the domestic orders backlog was substantially offset by an increase in international orders backlog, as the Company continued to see good project opportunities in its international markets.

Net earnings for the six months ended October 31, 2013 were $2,312,000, or $0.89 per diluted share, as compared to net earnings of $1,283,000, or $0.50 per diluted share, in the same period last year. Sales for the six months ended October 31, 2013 were $58,101,000, as compared to sales of $57,868,000, in the same period last year.  Domestic sales were $49,134,000, as compared to sales of $48,312,000 in the same period last year.  International sales were $8,967,000, as compared to sales of $9,556,000 in the same period last year.

Cash on hand was $5.9 million at the end of the quarter, as compared to $6.5 million at the end of the same period last year.  Short-term borrowings under the Company's bank line of credit were $2.5 million, as compared to $5.3 million at the end of the same period last year, and total bank borrowings were $7.5 million, as compared to $9.3 million. The debt-to-equity ratio was .24-to-1, as compared to .30-to-1 at the end of the same period last year. Working capital was $25.0 million, as compared to $24.2 million at the end of the same period last year.

"We had a good quarter, both internationally and domestically," said David M. Rausch, Kewaunee's Chief Executive Officer. "Although sales and earnings were below the pace of the past several quarters, a good portion of the sales decline was related to our strategy to improve product mix and margins. We also continue to make excellent progress in strengthening our relationships with laboratory planners and architects. Through this process we are gaining a better understanding of their needs and desired products, which increases their preference for the Kewaunee brand.

"Looking forward to the second half of our fiscal year, we expect the domestic marketplace will continue to be challenging due to the uncertainty in the economy and the resulting softening in demand for our products. We continue to pursue new sales opportunities, domestically and internationally, and maintain our focus on cost savings initiatives throughout the organization. It should be pointed out that our third quarter is normally the slowest due to construction cycles and the large number of holidays. The comparable third quarter of last year was an exception to this norm, as several large international projects shipped during that quarter."

Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets. One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to, competitive and general economic conditions, both domestically and internationally; changes in customer demands; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; and acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. Additional information concerning these and other factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 Kewaunee Scientific CorporationConsolidated Statements of Operations (Unaudited)(in thousands, except per share data)Three months endedSix months ended October 31,October 31,2013201220132012Net sales$
57,868Cost of products sold21,20525,95846,63247,398Gross profit4,8935,22711,46910,470Operating expenses3,7594,0137,9038,151Operating earnings1,1341,2143,5662,319Other income90108170176Interest expense(72)(101)(160)(215)Earnings before income taxes1,1521,2213,5762,280Income tax expense4064141,213785Net earnings7468072,3631,495Less: net earnings attributable tothe noncontrolling interest2115851212Net earnings attributable to Kewaunee Scientific Corporation$
,283Net earnings per share attributable toKewaunee Scientific Corporation stockholdersBasic$
.50Weighted average number of commonshares outstandingBasic2,6062,5872,6012,584Diluted2,6332,6012,6182,592 Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets(in thousands)October 31,April 30,20132013Assets(Unaudited)Cash and cash equivalents$
5,811Restricted Cash603691Receivables, less allowances20,45025,884Inventories13,17413,203Prepaid expenses and other current assets1,8631,641Total Current Assets41,37447,230Net property, plant and equipment15,03815,098Other assets6,8316,414Total Assets$
8,742Liabilities and EquityShort-term borrowings and interest rate swap$
,997Current portion of long-term debt421200Accounts payable8,24710,406Other current liabilities4,9404,512Total Current Liabilities16,32722,115Other non-current liabilities15,35112,934Total Liabilities31,67835,049Noncontrolling interest2052,017Kewaunee Scientific Corporation equity31,36031,676Total Equity31,56533,693Total Liabilities and Equity$

D. Michael Parker 


SOURCE Kewaunee Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kewaunee Scientific Announces New Website
2. Kewaunee Scientific Reports Record Sales and Earnings for First Quarter
3. Donald F. Shaw Elected To Kewaunee Scientific Board Of Directors
4. Kewaunee Scientific Announces CEO Retirement and Appointment of Successor
5. Kewaunee Scientific Reports Improved Results for Third Quarter
6. Kewaunee Scientific Reports Record Sales for Second Quarter
7. Kewaunee Scientific Corporation Declares Quarterly Dividend
8. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
9. Anavex Appoints Alzheimers Industry Leader to Scientific Advisory Board
10. Susan Lisa Named Vice President Of Investor Relations Of Boston Scientific
11. Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):